Merck & Co. Stock News

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has approved PIMJETMI® (pimicotinib), a once-daily oral colony stimulating factor-1 receptor (CSF-1R) inhibitor, as a systemic treatment for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worse...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of positive results from the company's Phase 2b clinical trial that evaluated the safety and efficacy of three doses of once-weekly, subcutaneous efinopegdutide (4 mg, 7 mg and 10 mg), an investigational injectable GLP-1/glucagon receptor co-agonist, versus pl...

Global healthcare stocks fell Friday, hit by a rout that reached Europe and Asia and spread across sectors after hammering AI trades and U.S. markets earlier in the week.

The US Food and Drug Administration on Tuesday issued an emergency use authorization for Merck's Bravecto ​tablets to treat New World screwworm in dogs ‌and puppies, expanding treatment options to combat the parasite.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MERCK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of ENHANCE-3 (NCT07874815), a Phase 3 randomized clinical trial evaluating OHTUVAYRE (ensifentrine) for the prevention of chronic obstructive pulmonary disease (COPD) exacerbations in adult patients receiving standard of care (SOC) with a history...

Third-quarter profit came in at $5.07 billion, or $2.04 a share, compared with $5.79 billion, or $2.32 a share, a year earlier.

Merck topped third-quarter estimates and hiked its adjusted profit outlook. The company's immunotherapy Keytruda, including a newer injectable form of the drug called Qlex, posted stronger-than-expected sales.